Tumor angiogenesis machinery

Tumor angiogenesis machinery refers to the complex network of signaling pathways and cellular components that tumors utilize to stimulate the formation of new blood vessels, a process known as the 'angiogenic switch' (Hanahan & Weinberg, 2011, Cell). This machinery is primarily driven by the secretion of pro-angiogenic factors such as Vascular Endothelial Growth Factor (VEGF), Fibroblast Growth Factor (FGF), and Platelet-Derived Growth Factor (PDGF) in response to intratumoral hypoxia (NCI, 2023). These factors bind to their respective tyrosine kinase receptors on endothelial cells, triggering proliferation, migration, and tube formation (StatPearls, 2023). In the context of oncology, this system is a critical therapeutic focus, as inhibiting these pathways can deprive the tumor of oxygen and nutrients (PubMed, 2021). Therapeutic agents like Bevacizumab and Sunitinib target specific nodes within this machinery to normalize tumor vasculature or induce vessel regression (NIH, 2022). However, because the term 'machinery' encompasses a broad array of distinct molecular targets rather than a single protein, it is classified as a biological process or pathway rather than a specific therapeutic target. Consequently, drug development focuses on individual components like VEGFR-2 or VEGF-A rather than the machinery as a whole (Nature Reviews Drug Discovery, 2020).

Other names

Tumor neovascularizationAngiogenic switchTumor vascularization pathwayAngiogenesis signaling network

Inhibition of pro-angiogenic signaling through the neutralization of growth factors (e.g., VEGF-A) or the competitive blockade of their cognate receptor tyrosine kinases (e.g., VEGFR-2) to suppress the formation of new blood vessels.